Caffeine's Effect on Attention

April 7, 2015 updated by: Société des Produits Nestlé (SPN)

The Effect of Caffeine on Attention

The purpose of this study is to determine whether caffeine improves attention.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Single centre single dose cross-over, placebo-controlled, double blind, randomized trial with two treatment conditions : caffeine and placebo

Study Type

Interventional

Enrollment (Actual)

71

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
    • CL
      • Leiden, CL, Netherlands, 2333
        • Center for Human Drug Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Healthy male and female Aged 40-60 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Mannitol administered at visit 1 and at visit 2
Other: Food
Active group
Other Names:
  • Caffeine
Other: Food
Control group
Other Names:
  • Placebo
Active Comparator: caffeine
caffeine administered at visit 1 and at visit 2
Other: Food
Active group
Other Names:
  • Caffeine
Other: Food
Control group
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Attention test: milliseconds and index of stimulus sensitivity
Time Frame: duration 10 days from screening to last visit (V2)
duration 10 days from screening to last visit (V2)

Secondary Outcome Measures

Outcome Measure
Time Frame
Central Nervous System :response time.
Time Frame: duration: 10 days from screening to last visit (V2)
duration: 10 days from screening to last visit (V2)
Mood measures: Visual Analog scale.
Time Frame: duration 10 days from screening to last visit V2
duration 10 days from screening to last visit V2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Société des Produits Nestlé (SPN)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

September 24, 2014

First Submitted That Met QC Criteria

October 9, 2014

First Posted (Estimate)

October 15, 2014

Study Record Updates

Last Update Posted (Estimate)

April 8, 2015

Last Update Submitted That Met QC Criteria

April 7, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 14.12.NRC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe